Price T Rowe Associates Inc. MD Has $47,000 Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS)

Price T Rowe Associates Inc. MD lessened its stake in Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) by 98.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 29,597 shares of the biopharmaceutical company's stock after selling 2,121,474 shares during the quarter. Price T Rowe Associates Inc. MD's holdings in Regulus Therapeutics were worth $47,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. PEAK6 LLC acquired a new stake in shares of Regulus Therapeutics during the 4th quarter worth $95,000. JPMorgan Chase & Co. grew its holdings in shares of Regulus Therapeutics by 193.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company's stock worth $124,000 after purchasing an additional 52,059 shares in the last quarter. Barclays PLC grew its holdings in shares of Regulus Therapeutics by 285.2% during the 3rd quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company's stock worth $132,000 after purchasing an additional 62,549 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of Regulus Therapeutics by 20.5% during the 4th quarter. Renaissance Technologies LLC now owns 117,100 shares of the biopharmaceutical company's stock worth $185,000 after purchasing an additional 19,900 shares in the last quarter. Institutional investors and hedge funds own 92.38% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the company. Wells Fargo & Company reissued an "equal weight" rating and set a $9.00 target price on shares of Regulus Therapeutics in a report on Thursday, May 1st. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price objective on shares of Regulus Therapeutics in a research note on Friday, March 14th. Leerink Partnrs lowered Regulus Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 30th. Leerink Partners reaffirmed a "market perform" rating and issued a $7.00 price objective on shares of Regulus Therapeutics in a research note on Wednesday, April 30th. Finally, Canaccord Genuity Group reaffirmed a "hold" rating and issued a $11.00 price objective (down from $28.00) on shares of Regulus Therapeutics in a research note on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $8.50.

Regulus Therapeutics Stock Down 0.3%

Shares of RGLS stock traded down $0.02 during mid-day trading on Friday, reaching $7.89. 1,814,371 shares of the stock traded hands, compared to its average volume of 902,748. The stock's fifty day simple moving average is $4.06 and its two-hundred day simple moving average is $2.32. Regulus Therapeutics Inc. has a 1-year low of $0.83 and a 1-year high of $8.20. The company has a market cap of $546.26 million, a price-to-earnings ratio of -7.37 and a beta of 0.49.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.29) by $0.14. On average, equities research analysts anticipate that Regulus Therapeutics Inc. will post -0.88 EPS for the current fiscal year.

Regulus Therapeutics Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.